Zongli Zheng

Dr. Zongli Zheng is an Assistant Professor at MWLC since May 2017.

Photo of Zongli Zheng.


Dr. Zheng received his PhD degree in medical epidemiology from Karolinska Institutet in 2011 and completed a postdoctoral training at Massachusetts General Hospital and Harvard Medical School in 2015, with support from the Swedish Research Council International Postdoc Fellowship. 


Our contribution to precision medicine includes the invention of the AMP technology that enables gene fusion discovery and, following initial clinical implementations in top US hospitals (MSK Solid Fusion, MGH NGS Fusion, etc.), has now been adopted globally for robust clinical assays for gene fusion detection to guide targeted therapy for cancer patients. We have also developed the GUIDE-seq method that has become a reference for genome-wide unbiased profiling of CRISPR edits. Currently, we focus on:

  • Genome engineering – to characterize genome-wide CRISPR targeting profile and improve its genome editing precision for treating diseases rooted in altered DNA bases or chromosomal structure.
  • Single-cell genomics – to develop a scalable and integrated single-cell genomic characterization platform for functional screening and identification of therapeutic targets.

Group Members

Name Title/Position
Zongli Zheng Assistant Professor
Jinhuan Li Postdoctoral Researcher
Bang Wang Postdoctoral Researcher
Maggie Chow Research Officer
Jan Keung Research Officer
Limei Ai Research Assistant
Jerry Gan Research Assistant
Silvia Mak Research Assistant

Previous lab members

Qinle Zhang | Postdoc

Siyu Bao | Research Assistant

Athena Chu | Senior Research Assistant

Baifeng Zhang | Research Assistant

Chloe Bao | Research Assistant

Selected Publications

Full list: Google Scholar

  1. Tan Y#, Chu HY#, Bao S, Hoang DA, Kebede TF, Xiong W, Ji M, Shi J*, Zheng Z*.Rationally engineered Staphylococcus aureus Cas9 nucleases with high genome-wide specificity. PNAS (2019) 116:20969-20976.
  2. Choi GCG, Zhou P, Yuen CTL, Chan BKC, Xu F, Bao S, Chu HY, Thean D, Tan K, Wong KH, Zheng Z, Wong ASL. Combinatorial mutagenesis en masse optimizes the genome editing activities of SpCas9. Nature Methods (2019) 16:722-730.
  3. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature (2016) 529:490–495.
  4. Kleinstiver BP, Prew MS, Tsai SQ, Nguyen NT, Topkar VV, Zheng Z, Joung JK. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nature Biotechnology (2015) 33:1293-1298.
  5. Tsai SQ#, Zheng Z#, Nguyen NT, Liebers M, Topkar VV, Thapar V, Wyvekens N, Khayter C, Iafrate AJ, Le LP, Aryee MJ, Joung KJ. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nature Biotechnology (2015) 33:187–198.
  6. Shaw A, Ou S, Bang Y, Camidge R, Solomon B, Salgia R, Riely G, Varella-Garcia M, Shapiro G, Costa D, Doebele R, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve S, Tye L, Christensen J, Wilner K, Clark J, Iafrate AJ. Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. The New England Journal of Medicine (2014) 371:1963-1971.
  7. Zheng Z, Liebers M, Zhelyazkova B, Cao Y, Panditi D, Lynch KD, Chen J, Robinson HE, Shim HS, Chmielecki J, Pao W, Engelman JA, Iafrate AJ, Le LP. Anchored multiplex PCR for targeted next-generation sequencing. Nature Medicine (2014) 20:1479–1484.